title: Anticoagulant therapy during pregnancy for maternal and fetal acquired and inherited thrombophilia.
abstract: Thromboembolism is an infrequent, yet serious cause of both maternal and fetal morbidity and death during pregnancy and the puerperium. Antithrombotic treatment and prophylaxis both before and during pregnancy are based on unfractionated heparin (UH), low-molecularweight heparin (LMWH), Warfarin and Aspirin. The prevalence and severity of thromboembolism during pregnancy and puerperium warrant special consideration of management and therapy. Such therapy includes the treatment of acute thrombotic events and prophylaxis for those at increased risk of thrombotic events. This paper assesses the safety and efficacy of antithrombotic therapy during pregnancy and the peripartum period. Its cardiovascular and obstetric indications, the evidence of association between thrombophilias and adverse pregnancy outcome, regimens and maternal and fetal side-effects are also discussed.
authors.affiliation: Department of Clinical Sciences, Polytechnic University of Marche, Salesi Hospital via F. Corridoni 11, 60123 Ancona, Italy. s.giannubilo@univpm.it
authors.forename: S R
authors.initials: SR
authors.lastname: Giannubilo
authors.forename: A L
authors.initials: AL
authors.lastname: Tranquilli
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D001241:Aspirin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D015519:Bone Density / Q000187:drug effects; D001942:Breast Feeding; D002809:Chondroitin Sulfates / Q000009:adverse effects / Q000627:therapeutic use; D003871:Dermatan Sulfate / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D000077425:Fondaparinux; D006493:Heparin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects / Q000627:therapeutic use; D006497:Heparan Sulfate / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D011134:Polysaccharides / Q000009:adverse effects / Q000627:therapeutic use; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000188:drug therapy / Q000517:prevention & control; D013923:Thromboembolism / Q000188:drug therapy; D019851:Thrombophilia / Q000209:etiology*; D014859:Warfarin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D001241:Aspirin; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D000077425:Fondaparinux; D006493:Heparin; D006495:Heparin, Low-Molecular-Weight; D006497:Heparan Sulfate; D011134:Polysaccharides; D014859:Warfarin; C035838:danaparoid